Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases.

Abstract

Porokeratosis is a group of cutaneous disorders of keratinization characterized by a predisposition to malignant transformation. The condition, which may be associated with immune suppression, is usually resistant to therapy and has a high frequency of recurrence. Imiquimod, a potent topical immune response modifier with antiviral, antitumor, and immunoregulatory properties, is currently approved for the treatment of external anogenital warts and actinic keratosis. However, there have been also several reports demonstrating its efficacy in a variety of premalignant and malignant conditions. We report on 2 cases with immunosuppression-associated porokeratosis successfully treated with 5% topical imiquimod application.

• Authors: Zülal Erbagci, A Almila Tuncel, Ibrahim Erbagci
• Journal: Journal of drugs in dermatology : JDD (J Drugs Dermatol) 2006 Jul-Aug Vol. 5 Issue 7 Pg. 668-71 ISSN: 1545-9616 [Print] United States
• PMID: 16865875 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Aminoquinolines
• Imiquimod

Topics

• Adjuvants, Immunologic (administration & dosage, therapeutic use)
• Administration, Topical
• Adult
• Aminoquinolines (administration & dosage, therapeutic use)
• Biopsy
• Diabetes Mellitus, Type 2 (complications)
• Female
• Humans
• Imiquimod
• Immunosuppression Therapy (adverse effects)
• Male
• Middle Aged
• Porokeratosis (drug therapy, pathology)
• Treatment Outcome